Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9368MR)

This product GTTS-WQ9368MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Colorectal Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9368MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9622MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ1671MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACZ885
GTTS-WQ8918MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ11065MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ1573MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ5702MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ9520MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ5230MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CB 2679d
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW